Accuray Provides Clarification on Recently Initiated Voluntary Recalls
SUNNYVALE, Calif., April 18, 2013
SUNNYVALE, Calif., April 18, 2013 /PRNewswire/ --Accuray Incorporated
(Nasdaq: ARAY) announced today clarification on two voluntary recalls that the
company initiated on March 19, 2013.
In keeping with its commitment to patient safety and total quality management,
Accuray has voluntarily implemented a recall of two separate components from
its CyberKnife® product line: the Iris™ Variable Aperture Collimator and the
RoboCouch® Patient Positioning System. The affected parts are manufactured by
third-party suppliers and are being removed from the system because they
failed to meet the company's specifications and standards for quality. The
company has notified impacted customers, and field service personnel have been
deployed to apply the corrections should they be necessary. These recalls
exclude the CyberKnife® M6 Series™ ^ Series.
The first recall affects 176 units of the Iris Variable Aperture Collimator
used in the CyberKnife System. Specifically, a defect was identified that
could potentially result in a shift to the central axis of the radiation beam,
posing a potential clinical impact to plans created using the smallest
collimators. The second recall affects 16 units of the RoboCouch® Patient
Positioning System used with the CyberKnife System. Specifically, the gear box
responsible for patient motions may be defective. All defective gearboxes have
been replaced. For both products, all affected sites have been notified and
corrective actions are being taken.
"The recent FDA recall announcement comes roughly a month after Accuray took
the necessary steps to voluntarily recall affected components. We are pleased
to report that no known injuries have been reported to date as a result of
these issues, and that we took the voluntary action to ensure that our product
quality and outstanding safety record are maintained," said Joy Sacmar, vice
president of regulatory affairs and quality assurance of Accuray."Events such
as these are not uncommon in our industry."
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range
of radiation therapy and radiosurgery treatments. For more information, please
Safe Harbor Statement
Statements made in this press release that are not statements of historical
fact are forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are not limited,
voluntary recalls, corrective actions, and safety record. Forward-looking
statements are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including risks detailed from
time to time under the heading "Risk Factors" in the company's report on Form
10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on
November 8, 2012 & February 6, 2013, and as updated periodically by our other
filings. Forward-looking statements speak only as of the date the statements
are made and are based on information available to the Company at the time
those statements are made and/or management's good faith belief as of that
time with respect to future events. The Company assumes no obligation to
update forward-looking statements to reflect actual performance or results,
changes in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.
Accordingly, investors should not place undue reliance on any forward-looking
SOURCE Accuray Incorporated
Contact: Lynn Pieper, Investor Relations, +1-415-202-5678,
Lynn.email@example.com; Rebecca Phillips, Public Relations Manager,
Press spacebar to pause and continue. Press esc to stop.